Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 10/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046722 | 0.96 | PTGER2 (0.59) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL27547779 | 0.94 | PTGER2 (0.55) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13398810 | 0.92 | PTGER2 (0.53) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5043193 | 0.91 | TAS2R14 (0.56) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5046568 | 0.91 | PTGER2 (0.54) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5046576 | 0.90 | PTGER2 (0.55) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5050266 | 0.90 | TAS2R14 (0.49) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5046454 | 0.89 | PTGER2 (0.55) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13398750 | 0.87 | PTGER2 (0.52) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13626605 | 0.87 | PTGER2 (0.51) | PTGER2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| CN-1275123-A | Prostaglandin agonists and their use to treat bone disorders | PFIZER (US) | 2000-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045545-A1 | EP2 AGONISTS | PTGER2, PTGER1, PTGIR | PTGER2 1/4885CA12 4207/4885CA1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.